Cardiac-specific overexpression of catalase prevents diabetes-induced pathological changes by inhibiting NF-kappaB signaling activation in the heart
Talking exclusively to ET on the sidelines of #BioAsia2026 in Hyderabad, Ramana emphasised that cost competitiveness will be critical for sustained participation in this fast-growing market
(e) Perimenopausal context
Document on a comprehensive approach to type 2 diabetes mellitus
Although shortages of brand-name GLP-1 therapies, such as Novo Nordisks semaglutide products Ozempic and Wegovy and Eli Lillys tirzepatide offerings Zepbound and Mounjaro, have officially been resolved, some telehealth firms, including Hims & Hers, have continued offering compounded versions
But the clinical evidence remains incomplete, and understanding where this product fits requires examining what GLP-1 actually does, how traditional agonists work, and what biomimetic alternatives can realistically achieve